Genetic studies of accelerometer-based sleep measures yield new insights into human sleep behaviour by Jones, SE et al.
ARTICLE
Genetic studies of accelerometer-based sleep
measures yield new insights into human sleep
behaviour
Samuel E. Jones et al.#
Sleep is an essential human function but its regulation is poorly understood. Using accel-
erometer data from 85,670 UK Biobank participants, we perform a genome-wide association
study of 8 derived sleep traits representing sleep quality, quantity and timing, and validate our
findings in 5,819 individuals. We identify 47 genetic associations at P < 5 × 10−8, of which 20
reach a stricter threshold of P < 8 × 10−10. These include 26 novel associations with measures
of sleep quality and 10 with nocturnal sleep duration. The majority of identified variants
associate with a single sleep trait, except for variants previously associated with restless legs
syndrome. For sleep duration we identify a missense variant (p.Tyr727Cys) in PDE11A as the
likely causal variant. As a group, sleep quality loci are enriched for serotonin processing
genes. Although accelerometer-derived measures of sleep are imperfect and may be affected
by restless legs syndrome, these findings provide new biological insights into sleep compared
to previous efforts based on self-report sleep measures.
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S leep is an important human function, but many aspects ofthe mechanisms that regulate it remain poorly understood.Adequate sleep is important for health and wellbeing, and
changes in sleep quality, quantity and timing are strongly asso-
ciated with several human diseases and psychiatric disorders1–5.
Identifying genetic variants influencing sleep traits will provide
new insights into the molecular regulation of sleep in humans and
help to establish the genetic contribution to causal links between
sleep and associated chronic diseases, such as diabetes and obe-
sity6–10.
Genome-wide association studies (GWAS) are an important first
step towards the discovery of new biological mechanisms of com-
plex traits. Previous large-scale genetic studies of sleep traits have
relied on self-reported measures. For example, using questionnaire
data from 47,180 individuals, the CHARGE consortium identified
the first common genetic variant, near PAX8, robustly associated
with sleep duration11. Subsequent studies in up to 128,286 indivi-
duals using the interim data release of the UK Biobank identified
two additional sleep duration loci12,13 and a parallel analysis of the
full UK Biobank release of 446,118 individuals identified a total of
78 associated loci14. Genetic associations have also been identified
for other self-reported sleep traits, including chronotype12,15,16,
insomnia, and daytime sleepiness13,17–21.
Although the reported associations revealed relevant pathways
related to mechanisms underlying sleep regulation, in large-scale
studies self-report measures are typically based on a limited
number of questions that only approximate a limited number of
sleep traits and may be subject to bias related to an individual’s
perception and recall of sleeping patterns22–26. Polysomnography
(PSG) is regarded as the gold standard method of quantifying
nocturnal sleep traits, but it is impractical to perform in large
cohorts. Additionally, PSG is relatively burdensome, since it
involves the use of complex equipment and experimental settings
to represent individual’s habitual sleep, making it less suitable for
measuring sleep over multiple nights and capturing inter-daily
variability. By contrast, research-grade activity monitors (accel-
erometers), also known as actigraphy devices, are more objective
and may provide cost-effective estimates of sleep for large studies.
To date, studies of limited sample size have been performed and
focussed on daytime activity27,28. The UK Biobank study is a
unique resource collecting vast amounts of clinical, biomarker,
and questionnaire data on ~500,000 UK residents. Of these,
103,000 participants wore activity monitors continuously for up
to 7 days. This provides an opportunity to derive accelerometer-
based estimates of sleep quality, quantity and timing and to assess
the genetics of sleep traits.
In this study, we identify genetic variants associated with
accelerometer-derived measures of sleep and rest-activity patterns
and use them to further understand the biology of sleep. We use
accelerometer data from the UK Biobank to extract estimates of
sleep characteristics using a heuristic method previously com-
pared against independent PSG and sleep-diary datasets. These
estimates have previously been demonstrated to be correlated
with polysomnography and sleep diaries29,30. We analyse a total
of eight accelerometer-based measures of sleep and activity tim-
ing. These include measures representative of sleep quality,
including sleep efficiency (sleep duration divided by the time
between the start and end of the first and last nocturnal inactivity
period, respectively) and the number of nocturnal sleep episodes.
In addition, we derive measures of timing (sleep midpoint, timing
of the least-active 5 h (L5), and timing of the most-active 10 h
(M10)), and duration (diurnal inactivity and nocturnal sleep
duration and variability). We present a GWAS in 85,670 UK
Biobank participants and validate our findings in three inde-
pendent studies. Our analysis primarily focuses on traits that
cannot be captured, or are unavailable, from self-report sleep
measures, and are likely to be underpowered for GWAS in studies
with PSG data due to limited sample sizes.
Results
Sleep quality and quantity are uncorrelated with timing.
Descriptive statistics and correlations between the eight
accelerometer-derived phenotypes are shown in Table 1 and Sup-
plementary Table 1. We observed little phenotypic correlation (R)
between measures of sleep timing and measures of nocturnal sleep
duration and quality (−0.10 ≤ R ≤ 0.12). These negligible or limited
correlations between timing and duration are consistent with data
from self-reported chronotype and sleep duration (R=−0.01).
We also observed limited correlation between sleep duration and
sleep quality as represented by the number of nocturnal sleep epi-
sodes (R= 0.14) but observed a stronger correlation between sleep
duration and sleep efficiency (R= 0.57). The correlations between
self-reported sleep duration and accelerometer-derived sleep dura-
tion was 0.19 and between self-reported chronotype (morningness)
and L5 timing was −0.29.
Accelerometer-derived sleep pattern estimates are heritable. To
estimate the proportion of variance attributable to genetic factors
for a given trait, we used BOLT-REML to estimate SNP-based
heritability (h2SNP) (Table 2). The h2SNP estimates ranged from 2.8%
(95% CI 2.0%, 3.6%) for variation in sleep duration (defined as the
standard deviation of accelerometer-derived sleep duration across
all nights), to 22.3% (95% CI 21.5%, 23.1%) for number of noc-
turnal sleep episodes. For sleep duration, we observed higher her-
itability using the accelerometer-derived measure (h2SNP= 19.0%,
95% CI 18.2%, 19.8%) in comparison to self-report sleep duration
(h2SNP= 8.8%, 95% CI 8.6%, 9.0%). The heritability estimates for
sleep and activity timings (maximum h2SNP= 11.7%, 95% CI
Table 1 Descriptive statistics of sleep and activity measures derived from accelerometer data
Measure Mean S.D. Min Max N
L5 timing (hours from previous midnight) 27.32 1.07 12.29 35.35 85,830
M10 timing (hours from previous midnight) 13.70 1.21 0.26 23.44 85,723
Sleep midpoint (hours from previous midnight) 26.99 0.91 16.25 31.98 85,502
Sleep duration mean (hours) 7.30 0.86 3.00 11.87 85,502
Sleep duration (SD; (hours)) 0.93 0.57 0.00 7.26 85,068
Sleep efficiency (%) 76.18 7.18 28.74 100.00 85,502
Number of sleep episodes 17.25 3.59 5.14 29.86 85,502
Diurnal inactivity duration 0.97 0.68 0 9.21 85,502
Units for the midpoint of the least-active 5 h (L5), midpoint of most-active 10 h (M10), sleep duration, sleep duration variation (SD), sleep midpoint and diurnal inactivity are in hours. Sleep efficiency is a
ratio and number of sleep episodes is a count
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10.9%, 12.5%) were lower than for self-report chronotype (h2SNP=
13.7%, 95% CI 13.3%, 14.0%)31.
Low genetic correlation between sleep duration estimates. To
quantify the genetic overlap between accelerometer-derived and
self-reported sleep traits, we performed genetic correlation
analyses using LD-score regression as implemented in LD-Hub32.
We observed strong genetic correlations of L5, M10 and sleep
midpoint timing with self-report chronotype (rG > 0.79), and
weaker genetic correlation between accelerometer-derived versus
self-reported sleep duration (rG= 0.43). This observation may be
due to differences in the genetic contribution to variation in self-
reported versus accelerometer-derived sleep duration or differ-
ences in the accuracy of self-reported phenotypes.
Forty-seven genetic associations identified for sleep traits. To
identify genetic loci associated with accelerometer-derived sleep
traits, we performed a genome-wide association analysis of
11,977,111 variants in up to 85,670 individuals for the eight
accelerometer-derived sleep traits. We identified 47 genetic asso-
ciations across seven of the phenotypes at the standard GWAS
threshold (P < 5 × 10−8). Among these associations, 20 reached a
more stringent threshold of P < 8 × 10−10. We estimate that this
threshold reflects a better type 1 error rate to account for the
approximate number of independent genetic variants analysed31
and the 8 accelerometer-based traits (Table 3 and Supplementary
Table 2 Heritability estimates of derived sleep variables
from BOLT-REML
Sleep variable h2 95% CI
Sleep duration 0.190 0.182–0.198
Sleep duration variability (SD) 0.028 0.020–0.036
Number of nocturnal sleep episodes 0.223 0.215–0.231
Sleep efficiency 0.130 0.122–0.138
L5 timing 0.117 0.109–0.125
M10 timing 0.087 0.079–0.095
Sleep midpoint timing 0.101 0.093–0.109
Diurnal inactivity 0.148 0.134–0.161
Table 3 Summary statistics for 47 genetic associations identified in the UK Biobank reaching P < 5 × 10−8
TRAIT SNP Chr BP (hg19) EA/OA Freq BETA SE P Gene region
L5 timing rs1144566 1 182,569,626 C/T 0.970 0.096 0.014 8E-12 RGS16/RNASEL
L5 timing rs113851554 2 66,750,564 T/G 0.057 0.133 0.011 2E-35 MEIS1a
L5 timing rs12991815 2 68,071,990 C/G 0.424 0.029 0.005 2E-09 C1Da
L5 timing rs9369062 6 38,437,303 A/C 0.708 0.039 0.005 9E-14 BTBD9a
L5 timing rs4882315 12 38,458,906 T/C 0.507 0.027 0.005 2E-08 CPNE8/ALG10B
L5 timing rs12927162 16 52,684,916 G/A 0.277 0.029 0.005 3E-08 TOX3a
M10 timing rs1973293 12 38,679,575 C/T 0.481 0.029 0.005 1E-09 CPNE8/ALG10B
Sleep duration rs2660302 1 98,520,219 A/T 0.811 0.041 0.006 9E-12 DPYD
Sleep duration rs113851554 2 66,750,564 G/T 0.943 0.110 0.011 2E-25 MEIS1a
Sleep duration rs62158170 2 114,082,175 G/A 0.217 0.054 0.006 3E-21 PAX8
Sleep duration rs17400325 2 178,565,913 T/C 0.958 0.066 0.012 2E-08 PDE11A
Sleep duration rs72828540 6 19,102,286 T/C 0.752 0.041 0.005 1E-13 LOC101928519
Sleep duration rs9369062 6 38,437,303 C/A 0.292 0.033 0.005 2E-10 BTBD9a
Sleep duration rs2975734 8 10,090,097 C/G 0.561 0.027 0.005 1E-08 MSRA
Sleep duration rs13282541 8 41,723,550 C/T 0.739 0.032 0.005 4E-09 ANK1
Sleep duration rs2880370 8 105,987,057 A/T 0.670 0.028 0.005 2E-08 LRP12/ZFPM2
Sleep duration rs800165 12 67,645,219 C/T 0.343 0.028 0.005 3E-08 CAND1
Sleep duration rs10138240 14 63,353,479 G/C 0.514 0.029 0.005 7E-10 KCNH5
Sleep midpoint rs11892220 2 231,691,067 T/A 0.339 0.029 0.005 3E-08 CAB39
Sleep efficiency rs113851554 2 66,750,564 G/T 0.943 0.101 0.011 5E-22 MEIS1a
Sleep efficiency rs62158169 2 114,081,827 T/C 0.216 0.032 0.006 2E-08 PAX8
Sleep efficiency rs17400325 2 178,565,913 T/C 0.958 0.074 0.012 2E-10 PDE11A
Sleep efficiency rs13094687 3 52,450,043 G/A 0.315 0.029 0.005 1E-08 PHF7
Sleep efficiency rs13080973 3 138,596,050 G/A 0.202 0.032 0.006 3E-08 FOXL2
No. sleep episodes rs12714404 2 282,462 T/G 0.283 0.037 0.005 1E-12 ACP1/SH3YL1
No. sleep episodes rs310727 3 4,336,589 T/C 0.475 0.026 0.005 3E-08 SUMF1/SETMAR
No. sleep episodes rs55754932 3 87,847,754 C/A 0.284 0.037 0.005 2E-12 HTR1F
No. sleep episodes rs9864672 3 137,076,353 T/C 0.522 0.029 0.005 2E-10 IL20RB/SOX14
No. sleep episodes rs4974697 4 2,473,092 T/A 0.390 0.026 0.005 5E-08 RNF4
No. sleep episodes rs7377083 4 102,708,997 A/C 0.430 0.029 0.005 2E-09 BANK1
No. sleep episodes rs749100 5 63,307,862 A/G 0.582 0.033 0.005 9E-12 HTR1A/RNF180
No. sleep episodes rs9341399 6 73,773,644 C/T 0.936 0.066 0.010 6E-12 KCNQ5
No. sleep episodes rs1889978 6 124,771,233 C/T 0.485 0.027 0.005 5E-09 NKAIN2
No. sleep episodes rs2141277 7 39,099,178 A/G 0.478 0.026 0.005 1E-08 POU6F2
No. sleep episodes rs10233848 7 103,122,645 G/A 0.293 0.035 0.005 2E-11 RELN
No. sleep episodes rs1124116 10 99,371,147 A/G 0.730 0.031 0.005 2E-09 HOGA1/MORN4
No. sleep episodes rs4755731 11 43,685,168 G/A 0.431 0.028 0.005 3E-09 HSD17B12
No. sleep episodes rs3751837 16 3,583,173 C/T 0.781 0.033 0.006 4E-09 CLUAP1
No. sleep episodes rs8045740 16 20,262,776 G/T 0.868 0.052 0.007 6E-14 GPR139
No. sleep episodes rs11078917 17 37,746,359 A/C 0.279 0.029 0.005 3E-08 NEUROD2
No. sleep episodes rs11082030 18 35,501,739 T/C 0.725 0.030 0.005 8E-09 CELF4
No. sleep episodes rs8098424 18 52,458,218 G/A 0.619 0.027 0.005 1E-08 RAB27B
No. sleep episodes rs76753486 19 42,684,264 T/C 0.084 0.047 0.008 2E-08 DEDD2/ZNF526
No. sleep episodes rs429358 19 45,411,941 T/C 0.848 0.036 0.007 4E-08 APOE
No. sleep episodes rs12479469 20 61,145,196 A/G 0.342 0.031 0.005 4E-10 MIR133A2
Diurnal inactivity rs17805200 9 13,764,434 C/T 0.272 0.031 0.005 5E-09 MPDZ/NFIB
Diurnal inactivity rs7155227 14 63,365,094 T/G 0.523 0.033 0.005 2E-12 KCNH5
CHR chromosome, BP base-pair position (GRCh37/hg19), EA/OA effect allele/other allele, Freq effect allele frequency, SE standard error, L5 timing midpoint of least-active 5 h, M10 timing midpoint of
most-active 10 h, No. sleep episodes number of nocturnal sleep episodes
aLocus previously reported for restless legs syndrome35
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Figs. 1 and 2). Twenty-six associations were observed for sleep
quality measures, including 21 variants associated with number of
nocturnal sleep episodes and five associated with sleep efficiency
(8 and 2 at P < 8 × 10−10, respectively). An additional eight genetic
associations were identified for sleep and activity timing. These
included six associated with L5 timing, one associated with M10
timing, and one associated with midpoint sleep. Only three
associations with L5 timing were detected at P < 8 × 10−10. Finally,
for sleep duration we observed 13 associations—11 for sleep
duration and 2 associated with diurnal inactivity (6 and 1 at P <
8 × 10−10, respectively). Of these 47 associations reaching P < 5 ×
10−8 and the 20 associations reaching P < 8 × 10−10, 31 and 9
were not previously reported in studies based on self-report
measures, respectively (Table 3). The variance explained by all the
discovered loci ranged from 0.04% for sleep midpoint timing to
0.8% for number of nocturnal sleep episodes. The lambda GC
observed across these analyses ranged from 1.03 (sleep duration
variability) to 1.14 (number of nocturnal sleep episodes), while
LD-score intercepts ranged from 1.03 (diurnal inactivity) to 1.07
(sleep midpoint timing). Given the median χ2 test-statistic can be
inflated for polygenic traits as sample size increases, the LD-score
intercepts suggest limited inflation of test statistics observed is
more likely to due to the polygenicity of the phenotype tested over
and above population stratification33,34.
Replication of 47 genetic associations in 5819 individuals. We
attempted to replicate our findings in up to 5819 adults from the
Whitehall II (N= 2,144), CoLaus (N= 2,257), and Rotterdam
Study (subsample from RS-I, RS-II and RS-III, N= 1,418) who had
worn similar wrist-worn accelerometer devices for a comparable
duration as the UK Biobank participants. Individual study and
meta-analysis results for the three replication studies are presented
in Supplementary Data 1. Of the 47 associations, the signal near
GPR139 (rs8045740) reached Bonferroni significance (P= 0.001)
and 11 were associated at P < 0.05 after meta-analysis of the
replication studies. Given the limited power to detect single SNP
associations in the replication meta-analysis, we next examined the
directional consistency of allele effect estimates. Of the 20 asso-
ciations reaching P < 8 × 10−10, 18 were directionally consistent in
the replication cohort meta-analyses (Pbinomial= 3 × 10−4). Of the
additional 27 signals, 18 were directionally consistent in the
replication meta-analysis (Pbinomial= 0.03). Finally, for traits with
more than one independent lead SNP associated at P < 5 × 10−8 in
the UK Biobank (Table 3), we combined the effects of the
lead SNPs on the respective sleep trait (aligned to the trait
increasing allele) and tested them in the replication data. In the
combined-effects analysis, we observed overall associations with
sleep duration (P= 0.008), sleep efficiency (P= 3 × 10−4), number
of nocturnal sleep episodes (P= 2 × 10−6), and sleep timing (P=
0.034) (Supplementary Data 2).
The genetics of sleep quality overlaps with sleep disorders. Of
the five variants associated with sleep efficiency, a measure of
sleep quality, one was the strongly associated PAX8 sleep duration
signal11 (rs62158169, P= 2 × 10−8) and one was a restless legs
syndrome/insomnia-associated signal (MEIS1)18,35 (rs113851554,
P= 5 × 10−22). Of the 20 loci associated with number of noc-
turnal sleep episodes, one is represented by the APOE variant
(rs429358). This variant is a proxy for the APOE ε4 risk allele that
is strongly associated with late-onset Alzheimer’s disease and
cognitive decline36. The ε4 allele is associated with a reduced
number of nocturnal sleep episodes (−0.13 sleep episodes; 95%
CI: −0.16, −0.11; P= 4 × 10−8). This finding is strengthened by
additional analyses of the ε2, ε3 and ε4 APOE Alzheimer’s disease
risk alleles, with an overall reduction in the number of nocturnal
sleep episodes observed with higher risk haplotypes (F(5, 72,578)
= 5.36, P= 0.001) (Supplementary Table 2). This finding is
inconsistent with the observational association between cognitive
decline in older age and poorer sleep quality37–40. One possible
explanation for this finding is ascertainment bias in the UK
Biobank whereby carriers of ε4 risk allele are protected from
cognitive decline through other factors. We also noted that the
APOE ε4 risk allele was nominally associated (P < 0.05) with sleep
timing (L5, −1.8 min per allele, P= 4 × 10−6), sleep midpoint
(−0.6 min per allele; P= 0.002), sleep duration (−1.1 min per
allele, P= 7 × 10−4), and diurnal inactivity (−1.0 min per allele,
P= 2 × 10−5). Apart from the APOE variant (rs429358), which
had double the effect size in the older half of the cohort (Sup-
plementary Table 2), there were minimal differences in effect
sizes in a range of sensitivity analyses, including removing indi-
viduals on sleep or depression medication, adjustments for BMI
and lifestyle factors, and splitting the cohort by median age
(Supplementary Data 3 and Supplementary Methods).
Six associations identified for estimates of sleep timing. We
identified six loci associated with L5 timing, of which three have
not previously been associated with self-report chronotype but
have been associated with restless legs syndrome35. The lead
variants at these three loci are in strong to modest LD with the
previously reported variants associated with restless legs syn-
drome (rs113851554, MEIS1, P= 2 × 10−35, LD r2= 1.00;
rs12991815, C1D, P= 2 × 10−9, LD r2= 0.96; rs9369062, BTBD9,
P= 9 × 10−14, LD r2= 0.49). The three variants that reside in
loci previously associated with self-report chronotype are in
strong to modest linkage disequilibrium with those previously
reported12,15,16 (rs1144566, RSG16, P= 8 × 10−12, LD r2 > 0.91;
rs12927162, TOX3, P= 3 × 10−8, LD r2= 1.00; rs4882315,
ALG10B, P= 2 × 10−8, LD r2= 0.58). The variant rs1144566 is a
missense coding change (p.His137Arg) in exon 5 of RSG16, a
known circadian rhythm gene, which contains variants strongly
associated with self-report chronotype12. In a parallel self-report
chronotype study in the UK Biobank, rs1144566 represented the
strongest association, with the T allele having a morningness
odds ratio of 1.26 (P= 2 × 10−95)31. In addition, variants in the
region of TOX3 have previously been associated with restless legs
syndrome35. However, our lead SNP (rs12927162) was not in
LD with the previously reported index variant at this locus
(rs45544231, LD r2= 0.004). There were minimal differences in
effect sizes when we performed a range of sensitivity analyses,
including removing individuals on depression medication,
adjustments for BMI and lifestyle factors and splitting the cohort
by median age (Supplementary Data 3 and Supplementary
Methods).
Ten novel loci associated with estimates of sleep duration. We
identified 11 loci associated with accelerometer-derived sleep
duration, including ten not previously reported to be associated
with self-report sleep duration, despite the fivefold increase in
sample size available for a parallel self-report sleep duration
GWAS study14 (Fig. 1 and Supplementary Data 4). This lower
overlap in signals is consistent with the lower genetic correlation
between self-reported and accelerometer-derived sleep duration
than between chronotype and accelerometer-derived measures of
sleep and activity timing. The lead variants representing the ten
new sleep duration loci all had the same direction and larger
effects in the accelerometer data compared to self-report data,
with effect sizes ranging from 1.3 to 5.9 min compared to 0.1 to
0.8 min (self-report P < 0.05), with the MEIS1 locus having the
strongest effect. Two of the ten new sleep duration signals,
rs113851554 in MEIS1 (P= 2 × 10−25) and rs9369062 in BTBD9
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(P= 2 × 10−10), have previously been associated with restless legs
syndrome. The one variant previously detected based on self-
report sleep duration, near PAX8, was the first variant to be
associated with sleep duration through GWAS11. The minor
PAX8 allele effect size was consistent across accelerometer-
derived measures of sleep duration (2.7 min per allele, 95% CI: 2.1
to 3.3, P= 3 × 10−21) and self-report sleep duration (2.4 min per
allele, 95% CI: 2.1 to 2.8, P= 7 × 10−49). We observed similar
effect sizes in a subset of 72,510 unrelated Europeans from the
UK Biobank, when removing individuals on depression medica-
tion and after adjusting for BMI and lifestyle factors. To confirm
that associations were not influenced by age-related differences in
sleep, we confirmed that there was also no difference in effect
sizes between younger and older individuals (above and below the
median age of 63.7 years) (Supplementary Data 3).
Fine-mapping analysis identifies likely causal variants. To
identify credible SNP sets likely to contain causal variants within
500 Kb of lead SNPs for each trait with a genetic association (P <
5 × 10−8) we used FINEMAP41 to identify credible sets of likely
causal SNPs (log10 Bayes Factor > 2) (Supplementary Data 5). This
approach places a probability on the likelihood that a variant,
among those tested, represents the causal allele. Two loci contained
a coding variant with a probability >80% for being the causal
variant. The first variant (rs17400325, MAF= 4.2%) was a mis-
sense variant (p.Tyr727Cys) in PDE11A, a phosphodiesterase
highly expressed in the hippocampus that was associated with sleep
duration (P= 2 × 10−8) and sleep efficiency (P= 2 × 10−10). The
other was the missense APOE variant, a proxy for the ε4 allele
known to predispose to Alzheimer’s disease and responsible for the
association signal with the number of nocturnal sleep episodes. Of
the remaining loci, five fine-mapped variants are eQTLs in the
Genotype-Tissue Expression (GTEx) project42. Of these only the
fine-mapped variant at the CLUAP1 locus associated with the
number of nocturnal sleep episodes (P= 4 × 10−9) was the lead
variant for the corresponding eQTL (log10 Bayes Factor= 2.48,
Pcausal= 0.72) (Supplementary Data 5). CLUAP1 has been gene
previously associated with photoreceptor maintenance43.
Serotonin pathway-related genes enriched at associated loci.
We used MAGMA44 to assess tissue enrichment of genes at
associated loci across the sleep traits. All traits showed an
enrichment of genes in the cerebellum (Supplementary Figs. 3
and 4). Loci associated with number of nocturnal sleep
episodes were enriched for genes involved in serotonin pathways
(PBonferroni= 3 × 10−4) (Supplementary Table 3).
Associated variants are implicated in restless legs syndrome.
We observed most variants to be associated with either sleep
quality, duration, or timing, but not combinations of these sleep
characteristics. However, the variant rs113851554 at the MEIS1
locus was associated with sleep quality (sleep efficiency), duration,
and timing (L5). In addition, the variant rs9369062 at the BTBD9
locus was associated with both sleep duration and L5 timing. Both
variants have previously been reported as associated with restless
legs syndrome (Fig. 2). To follow up this observation, we per-
formed Mendelian Randomisation using 20 variants associated
with restless legs syndrome in the discovery stage of the most
recent and largest genome-wide association study35. We tested
these 20 variants against all eight activity-monitor-derived sleep
traits and showed a clear causative association of restless legs
syndrome with all sleep traits. We also observed a causative
association of restless legs syndrome with self-report sleep
duration and chronotype, suggesting that variants associated with
restless legs syndrome were not artefacts of the accelerometer-
derived measures of sleep (Supplementary Data 6).
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Fig. 1 Comparison of SNP effect estimates on accelerometer and self-report
sleep duration. The effects for 11 genetic variants associated with
accelerometer-derived sleep duration against effect estimates from a
parallel GWAS of self-report sleep duration14 are presented. Error bars
represent the 95% confidence intervals for each effect estimate
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Fig. 2 Effects of restless legs syndrome-associated SNPs on derived sleep traits. Presented are the effect estimates for genetic variants associated with
a either L5 timing or sleep duration, b either sleep duration or the number of nocturnal sleep episodes, and c either L5 timing or sleep quality (number of
nocturnal sleep episodes or sleep efficiency). Variants previously associated with restless legs syndrome are highlighted in red. Effect estimates represent
standard deviations of the inverse-normal distribution of each trait. Error bars represent the 95% confidence intervals for each effect estimate
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Waist-hip-ratio causally influences sleep outcomes. To assess
causality of phenotypes, we used genetic correlations to prioritise
traits with evidence of genetic overlap for subsequent Mendelian
Randomisation analyses using LD-Hub32. We tested for genetic
correlations between the eight activity-monitor-derived measures
and 234 published GWAS studies across a range of diseases and
traits. Given previous reports that genetic correlations are similar
to phenotypic correlations45, this approach also enabled us to
analyse phenotypes under-represented, not recorded, or not well
defined within the UK Biobank. After adjustment for the number
of genetic correlations tested (8 × 234), we observed genetic cor-
relations between sleep traits and obesity and educational
attainment related traits (Supplementary Data 7). After adjusting
for the number of tests in the bi-directional MR analysis (100), we
observed evidence that higher waist-hip-ratio (adjusted for BMI)
is causally associated with lower sleep duration (PIVW= 5 × 10−6)
and lower sleep efficiency (PIVW= 3 × 10−4). In addition, we
observed higher educational attainment to be causally associated
with lower sleep duration (PIVW= 5 × 10−5). However, given the
genetic correlation and MR analyses are not independent, only
the causal association of waist-hip-ratio (adjusted for BMI) on
sleep duration remained significant after applying a more strin-
gent threshold (PIVW ≤ 3 × 10−5) to account for a maximum of
234 bi-directional MR analyses (Supplementary Data 8). We
observed no evidence of causal effects of accelerometer-based
sleep traits on outcomes tested (Supplementary Data 9).
Self-report and accelerometer sleep traits effects correlate. We
compared effects of variants associated with self-reported sleep
duration and chronotype identified in parallel GWAS analyses.
Overall, we observed directional consistency with the accelerometer-
derived measures. In a parallel GWAS of self-reported sleep dura-
tion in 446,118 individuals from the UK Biobank14, we identified 78
associated loci at P < 5 × 10−8. Sixty-seven (85.9%) of these SNPs
were directionally consistent between the self-report and activity-
monitor-derived sleep duration GWAS (Pbinomial= 6 × 10−11;
Fig. 3). Furthermore, in a parallel report31 we have shown that of
the 341 lead variants at self-reported chronotype loci, 310 (90.9%)
had a consistent direction of effect for accelerometer-derived mid-
point-sleep (Pbinomial= 5 × 10−59), 316 (92.7%) with L5 timing
(Pbinomial= 3 × 10−65) and 310 (90.9%) with M10 timing (Pbinomial
= 5 × 10−59). Figure 4 shows a scatter plot of self-reported asso-
ciated chronotype effects against L5 timing effects.
Discussion
Our analysis presents the largest-scale GWAS of multiple sleep
traits estimated from accelerometer data using our activity-
monitor sleep algorithm, with estimates previously demonstrated
to be highly correlated with polysomnography29,30. We have
identified 47 genetic associations at P < 5 × 10−8 across seven
traits representing sleep duration, quality and timing. These loci
included ten novel variants for sleep duration and 26 for sleep
quality not detected in larger studies of self-reported sleep traits.
Of the associated loci, a low-frequency (MAF= 4.2%) missense
variant (p.Tyr727Cys) at the PDE11A locus (rs17400325) was
associated with sleep duration and sleep efficiency. The variant
was associated with sleep duration (P= 0.004) in the meta-
analysis of the replication cohort. Fine-mapping provided a high
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Fig. 3 Comparison of effect estimates for SNPs associated with self-
reported sleep duration. The effect estimates for 78 genetic variants
associated with self-report sleep duration in a parallel GWAS effort14 are
plotted against the effect estimates on accelerometer-derived estimates of
sleep duration. Error bars represent the 95% confidence intervals for each
effect estimate
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Fig. 4 Comparisons of genetic effect estimates on morning person (binary chronotype) and L5 timing. Plotted are the genetic effect estimates for variants
associated with chronotype based on the latest self-report chronotype meta-analysis31 against accelerometer-derived estimates of L5 timing: a Three-
hundred fifty-one variants identified from the self-report chronotype meta-analysis and b six variants identified for L5 timing. Error bars represent the 95%
confidence intervals for each effect estimate. Chronotype effect estimates are reported for variants identified in the primary sample size meta-analysis
using effect sizes (lnOR morningness) derived in the secondary effect size meta-analysis
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probability (>90%) that this is the causal variant at the locus. This
variant has previously been associated with migraine and near-
sightedness (myopia) in a scan of 42 traits from 23andMe46. In
the UK Biobank the variant was not associated with migraine (P
= 0.44), consistent with the latest migraine meta-analysis where it
was not among the associated loci47, but was associated with
myopia (P= 9 × 10−10). The allele that associates with reduced
risk of myopia is associated with increased sleep efficiency and
duration. Protein truncating variants in PDE11A have been sug-
gested to cause adrenal hyperplasia;48 however, one of these
variants (R307X, rs76308115) is present at 0.5% frequency in the
UK Biobank (with 11 rare allele homozygotes) and is not asso-
ciated with sleep efficiency (P= 0.99) or duration (P= 0.54). This
suggests that if Tyr727Cys PDE11A is the causal variant at this
locus then it is an activating mutation. PDE11A is expressed in
the hippocampus and it has been suggested as a potential biolo-
gical target for interventions in neuropsychiatric disorders49.
Our analysis identified variants in loci that were enriched for
genes involved in the serotonin pathway—the strongest pathway
associated with sleep quality. Serotonergic transmission plays an
important role in sleep cycles50,51. High levels of serotonin are
associated with wakefulness and lower levels with sleep. Fur-
thermore, serotonin is synthesised by the pineal gland as a pro-
cessing step for melatonin production, a key hormone in
circadian rhythm regulation and sleep timing52.
A subset of variants previously associated with restless legs
syndrome were associated with sleep duration, quality and timing
measures. In the UK Biobank, restless legs syndrome was only
identified through the Hospital Episodes Statistics (HES) data
using the ICD-10 code G25.8 (Other specified extrapyramidal and
movement disorders), the parent category of the more specific
G25.81 code (Restless legs syndrome). Under the assumption that
all individuals reporting G25.8 had restless legs, we observed 38
individuals within our accelerometer subset. Removing these
individuals did not change our conclusions. Given that the same
variants are also associated with self-report measures of sleep
duration, chronotype and insomnia, this observation may not be
an artefact caused by limb movements during sleep. On the other
hand, the repetitive periodic limb movements (PLMS) that people
with RLS typically experience during sleep could have been
detected by the accelerometers and confounded the parameters.
Studies with more in-depth phenotyping of sleep disorders are
needed to more fully evaluate the contribution of RLS and PLMS
to sleep traits, especially in light of a recent paper showing that
associations with MEIS1 were only in those with RLS53.
Our Mendelian Randomisation analysis also provides some
evidence of a causative effect of higher waist-hip-ratio (adjusted
for BMI) on lower sleep duration and lower sleep efficiency. This
suggests that fat distribution plays a role in sleep, although there
was also a nominal causative association with BMI, which also
suggests a general role of overall adiposity. We also observed
evidence of a causative association between higher educational
attainment and lower sleep duration. Both the adiposity and
educational attainment MR results were robust to a range of MR
sensitivity analyses (Supplementary Data 8). We did not observe
evidence of a causal effect of accelerometer-derived sleep variables
on genetically correlated traits. This may be due to the relatively
limited power because of the relatively small number of genetic
instruments available.
Our data provide strong evidence that some accelerometer-
derived measures of sleep provide higher precision than self-
report measures, while for others there is little gain through
accelerometer-derived measurement with questionnaire data
being just as effective. For example, of the 11 accelerometer-based
sleep duration loci we identified, only one (the PAX8 variant) had
been previously identified in self-reported sleep duration GWAS
despite these studies having much larger sample sizes. Variants
with nominal evidence of association with self-reported sleep
duration had weaker effects. This difference may be due to
reporting biases related to the UK Biobank questionnaire (e.g.,
response was in hourly increments) and due to asking partici-
pants to include nap-time in their sleep duration. In contrast the
accelerometer-derived estimates of L5 timing, the least-active 5 h
of the day, correlated well with self-report estimates. These data
suggest that the answer to the very simple question “are you a
morning or evening person” provides similar power as wearing
accelerometers for 7 days and nights. In a parallel GWAS ana-
lysis, the PAX8 variant was also associated with self-report
insomnia20. In addition, five of the loci were nominally associated
(P < 0.05) with either self-report sleep duration or insomnia. At
least two of the sleep duration signals have been previously
associated with mental health disorders, including schizophrenia
and migraine46,54.
The Alzheimer’s disease risk allele at the APOE locus had
apparently paradoxical associations with sleep related traits.
Given the well-established association between the ε4 allele and
greater risk of Alzheimer’s disease, we would not expect asso-
ciations between this allele and higher sleep quality given pre-
vious associations of adverse sleeping patterns with cognitive
decline and Alzheimer’s disease4. A similar paradoxical associa-
tion was also reported recently in a study of over 2,300 men aged
over 65 with overnight PSG data that showed the total time in
stage N3 sleep was higher for individuals carrying two copies of
ε4 compared with those carrying one or zero copies55. Further-
more, a recent genetic study of physical activity also identified a
paradoxical association between the ε4 allele and increased levels
of physical activity56. The more likely explanations for these
associations we suggest are ascertainment and survival bias. The
UK Biobank participants ranged from 44 to 79 years of age when
wearing the accelerometer devices. Older UK Biobank partici-
pants, with the highest risk of cognitive decline with an ε4/ε4
haplotype and agreeing to an accelerometer-based experiment
could be protected from cognitive decline because of selection
bias due to other factors57. To participate in the UK Biobank
study and agree to accelerometer data collection several years
after study baseline is less likely to occur in individuals who are in
cognitive decline. As a result, the ε4 risk allele may present an
association with higher sleep quality. Consistent with this
potential bias, the ε4 allele association with reduced numbers of
nocturnal sleep episodes is stronger in older age. For example,
when splitting individuals by median age, the per allele effect on
number of sleep episodes was twice that of the older versus
younger group.
There are some limitations to this study. First, a sleep diary was
not collected by the UK Biobank participants, a traditional tool to
guide the start and end timing of nocturnal sleep episodes,
commonly used in actigraphy studies. We have developed and
used an open source method to overcome the lack of a sleep diary
that has been compared against polysomnography29,30 to esti-
mate sleep onset and waking up time. However, as no sleep diary
data exists it is hard to define bedtime prior to sleep, resulting in
the inability to characterise phenotypes such as sleep onset
latency (the time between going to bed and falling asleep). Sec-
ond, the activity monitors were worn up to 10 years from when
baseline data was collected. Despite this, the correlation between
self-report and activity measures of sleep duration was consistent
with previous studies, and the correlation did not differ based on
time between baseline (self-report time) and accelerometer wear
when splitting by time-difference deciles (r=−0.03, P= 0.94).
Third, due to relatively small sample sizes of replication studies,
we had limited power to replicate associations identified in the
UK Biobank. The variance explained by individual variants in the
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UK Biobank ranged from 0.03% to 0.19%, for which we had <63%
power to detect at a statistical threshold of P= 0.001 (accounting
for 47 tests) in the meta-analysis of 4,401 individuals. However,
we observed an enrichment for directional consistency in effect
estimates in the replication meta-analysis and in combined-effects
analyses identified associations for sleep duration, sleep efficiency,
number of nocturnal sleep episodes and sleep timing. Fourth, the
UK Biobank participants are not representative of the UK
population, as participants had a higher socio-economic position
overall and were healthier, on average, given the prevalence of
diseases among the participants57,58. This was particularly true of
the participants who took part in the activity-monitor study.
Finally, it is important to keep in mind that while accelerometry
provides a more objective means of assessing sleep and wake than
self-report, it has its own limitations. Measures of sleep using
actigraphy are intrinsically difficult to interpret, as awake and not
moving cannot be distinguished from sleep. Furthermore,
although small studies have shown limited effects of events that
disturb sleep (such as respiratory events or periodic limb move-
ments), the effect on large-scale data is difficult to assess. Mod-
erate to severe sleep apnea (≥15 apneas or hypopneas per hour of
sleep) and periodic limb movements in sleep (≥15 movements per
hour of sleep) are relatively common in individuals within the age
range of the present study59,60. Unfortunately, these conditions
were not captured well in the UK Biobank study, limiting the
possibility of evaluating the effects of such sleep disorders on
accelerometer-derived sleep traits. Future studies of PSG-derived
metrics of sleep, such as total sleep duration, sleep efficiency, and
proportions of sleep stages should be conducted. For people with
insomnia, accelerometry tends to overestimate sleep because time
spent lying still in bed awake attempting to sleep can be scored as
sleep61. However, most studies have relied on a devices that
measure a single axis of movement that could be more prone to
these errors, and our recent work suggests that newer triaxial
devices may be more accurate30.
In conclusion, we have performed the most comprehensive
GWAS of accelerometer-derived sleep measures to date. We
demonstrated that self-report measures are good proxies for
accelerometer-derived sleep measures. However, through the
investigation of accelerometer-derived sleep measures we found
additional loci not identified by previous self-report GWAS stu-
dies. These loci harbour likely causal variants associated with
poor sleep.
Methods
UK Biobank participants. The study population was drawn from the UK Biobank
study—a longitudinal population-based study of individuals living in the UK58.
Analyses were based on individuals estimated to be of European ancestry. Eur-
opean ancestry was defined through the projection of UK Biobank individuals into
the principal component space of the 1000 Genomes Project samples62 and sub-
sequent clustering based on a K-means approach, centring on the means of the first
four principal components.
Genetic data. Imputed genetic data was downloaded from the UK Biobank63. We
limited our analysis to 11,977,111 genetic variants imputed using the Haplotype
Reference Consortium imputation reference panel with a minimum minor allele
frequency (MAF) > 0.1% and imputation quality score (INFO) > 0.3.
Activity-monitor devices. A triaxial accelerometer device (Axivity AX3) was worn
between 2.8 and 9.7 years after study baseline by 103,711 individuals from the UK
Biobank for a continuous period of up to 7 days. Data collection and initial quality
checks were performed centrally by members of the UK Biobank study64. Of these
103,711 individuals, we excluded 11,067 individuals based on activity-monitor data
quality. This included individuals flagged by UK Biobank as having data problems
(field 90002), poor wear time (field 90015), poor calibration (field 90016), or unable
to calibrate activity data on the device worn itself requiring the use of other data
(field 90017). Individuals were also excluded if number of data recording errors
(field 90182), interrupted recording periods (field 90180), or duration of inter-
rupted recoding periods (field 90181) was greater than the respective variable’s 3rd
quartile+ 1.5 × IQR. Phenotypes determined using the SPT-window (all pheno-
types except L5 and M10 timing) had additional exclusions based on short (<3 h)
and long (>12 h) mean sleep duration and too low (≤5) or too high (≥30) mean
number of sleep episodes per night (see below). These additional exclusions were to
ensure that individuals with extreme (outlying), and likely incorrect, sleep char-
acteristics were not included in any subsequent analyses. A maximum of 85,723
individuals remained for our analyses.
Accelerometer data processing and sleep measure derivations. We derived
eight measures of sleep quality, quantity and timing. All measures were derived by
processing raw accelerometer data (.cwa). We first converted the .cwa files available
from the UK Biobank to .wav files using omconvert for signal calibration to
gravitational acceleration64,65 and interpolation64. The .wav files were processed
with the open source R package GGIR30 (https://doi.org/10.5281/zenodo.1175883
(Version v1.5-17)) to infer accelerometer non-wear time66, and extract the z-angle
across 5-s epochs from the time-series data for subsequent use in estimating the
sleep period time window30 and sleep episodes within it29.
The sleep period time window (SPT-window) was estimated using an algorithm
previously compared against PSG data and described30 and implemented in the
GGIR R package. Briefly, for each individual, median values of the absolute change
in estimated z-angle (representing the dorsal-ventral direction when the wrist is in
the anatomical position) across 5-min rolling windows were calculated across a 24-
h period, chosen to make the algorithm insensitive to accelerometer orientation.
The 10th percentile was incorporated into the threshold distinguishing movement
from non-movement. Bouts of inactivity lasting ≥ 30 min are recorded as inactivity
bouts. Inactivity bouts that are < 60 min apart are combined to form inactivity
blocks. The start and end of the longest block defined the start and end of the SPT-
window.
Sleep duration and variability were estimated based on sleep episodes within the
STP-window. Sleep episodes within the SPT-window were defined as periods of at
least 5 min with no change larger than 5° associated with the z-axis of the activity-
monitor, as motivated and described in van Hees et al.29. The summed duration of
all sleep episodes was used as indicator of sleep duration within the SPT-window.
The total duration over the activity-monitor wear time was averaged. Individuals
with an average sleep duration <3 h or >12 h were excluded from all analyses. In
addition, the standard deviation of sleep duration was also calculated and put
forward for statistical analysis for individuals with the maximum days (N= 7) of
accelerometer wear.
Sleep efficiency was calculated as sleep duration (defined above) divided by the
time elapsed between the start of the first inactivity bout and the end of the last
inactivity bout (which equals the SPT-window duration).
The number of nocturnal sleep episodes was defined as the number of sleep
episodes within the SPT-window. Individuals with an average number of nocturnal
sleep episodes ≤5 or ≥30 were excluded from all analyses.
Least-active 5 h (L5) timing was defined as the midpoint of the least-active 5 h
(L5) of each day. The least-active 5 h was defined as the 5-h period with the
minimum average acceleration. These periods were estimated using a rolling 5-h
time window. The midpoint was defined as the number of hours elapsed since the
previous midnight (for example, 7 p.m.= 19 and 2 a.m.= 26). Days with <16 h of
valid-wear time (as estimated by GGIR) were excluded from L5 estimates.
Most-active 10 h (M10) timing was defined as the midpoint of the most-active
10 h (M10) of each day. The most-active 10 h was defined as the 10-h period with
the maximum average acceleration. These periods were estimated using a rolling
10-h time window. The midpoint was defined as the number of hours elapsed since
the previous midnight. Days with < 16 h of valid-wear time (as estimated by GGIR)
were excluded from M10 estimates.
Sleep midpoint timing was calculated for each sleep period as the midpoint
between the start of the first detected sleep episode and the end of the last sleep
episode used to define the overall SPT-window (above). This variable is represented
as the number of hours from the previous midnight.
Diurnal inactivity was estimated by the total daily duration of estimated bouts
of inactivity that fell outside of the SPT-window. This measure captures very
inactive states such as napping and wakeful rest but not inactivity such as sitting
and reading or watching television, which are associated with a low but detectable
level of movement.
Comparison against self-reported sleep measures. We performed analyses of
self-reported measures of sleep. Self-reported measures analysed included (a) the
number of hours spent sleeping over a 24-h period (including naps); (b) insomnia;
(c) chronotype—where “definitely a ‘morning’’ person”, “more a ‘morning’’ than
‘evening’’ person”, “more an ‘evening’’ than a ‘morning’’ person”, “definitely an
‘evening’’ person” and “do not know”, were coded as 2, 1, −1, -2 and 0, respec-
tively, in our continuous variable.
SNP-based heritability analysis. We estimated the heritability of the eight
derived accelerometer traits using BOLT-REML (version 2.3.1)67. We used 524,307
high-quality genotyped single nucleotide polymorphisms (SNPs) (bi-allelic;
MAF ≥ 1%; HWE P > 1 × 10−6; non-missing in all genotype batches, total miss-
ingness <1.5% and not in a region of long-range LD68) to build the relatedness
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model and thus to estimate heritability. For LD structure information, we used the
default 1000 Genomes ‘LD-score’’ table provided with the BOLT-REML software.
Genome-wide association analyses. We performed all association tests in the UK
Biobank using BOLT-LMM v2.367, which applies a linear mixed model (LMM) to
adjust for the effects of population structure and individual relatedness, and enables
the inclusion of all related individuals in our white European subset, boosting our
power to detect associations. This meant a sample size of up to 85,670 individuals,
as opposed to a maximal set of 72,696 unrelated individuals. At runtime, all
phenotypes were first adjusted for age at accelerometry (estimated using month of
birth and date of first recording day), sex, study centre (categorical), season when
activity-monitor worn (categorical) and genotyping array (categorical; UK Bileve
array, UKB Axiom array interim release and UKB Axiom array full release). All
phenotypes except sleep duration variation were also adjusted for the number of
measurements used to calculate each participant’s measure (number of L5/M10
measures for L5/M10 timing, number of days for diurnal inactivity and number of
nights for all other phenotypes). The number of sleep episodes phenotype was
further adjusted for time in bed (length of SPT-window). Phenotypes were ana-
lysed on their original-scale and the inverse-normal-scale after transformation and
all results (except those that refer to interpretable effect sizes) are reported for the
inverse-normal scale analyses.
Replication of findings. Associations reaching P < 5 × 10−8 were followed up in
the CoLaus, Whitehall II and Rotterdam studies. The GENEActiv accelerometer
was used by the CoLaus and Whitehall II studies and worn on the wrist by the
participants. In the CoLaus study, 2967 individuals wore the accelerometer for up
to 14 days. Of these, 10 were excluded because of insufficient data, 234 excluded as
non-European, and a further 148 were excluded due to an average sleep duration of
<3 h or >12 h. A total of 2575 individuals remained for analysis of which 2257 had
genetic data. In the Whitehall II study, 2144 were available for analysis, with the
GENEActiv accelerometer worn for up to 7 days having performed the same
exclusions. The Rotterdam Study used the Actiwatch AW4 accelerometer device
(Cambridge Technology Ltd.). All 24‐h periods with more than three continuous
hours missing were excluded from the analyses to prevent a time‐of‐day effect.
Recordings were also excluded if consisting of <96 h (n= 109 excluded) or if
collected in a week of daylight-saving time (n= 26), resulting in 1734 persons of
which genetic data was available for 141869. For all replication studies, the deri-
vation of the sleep characteristics and the same overall- and trait-specific exclusion
criteria outlined above applied. Where available, accelerometer-derived phenotypes
were analysed both on the original-scale and inverse-normal scale. Genetic asso-
ciation analysis was based on imputed data (where available) and performed using
standard multiple linear regression. The covariates incorporated into the model
were the same as those used in the UK Biobank analysis. Overall summary statistics
were obtained through inverse-variance-based meta-analysis implemented in
METAL70. Combined variant effects on respective traits were subsequently cal-
culated using the ‘metan’’ function in STATA using the betas and standard errors
obtained through the primary meta-analysis of the three replication studies.
Gene-set, tissue enrichment and GWAS catalogue analyses. Gene-set analyses
and tissue expression analyses were performed using MAGMA44 as implemented
in the online Functional Mapping and Annotation of Genome-Wide Association
Studies (FUMA) tool71. For lead and candidate SNP identification, the default
settings were used: lead variants were required to have a minimum P-value of 5 ×
10−8; r2 threshold for defining LD structure of lead variants was set to 0.6; the
maximum P-value cutoff was set to 0.05; the reference panel population was chosen
to be 1000 Genomes Phase 3; variants in the reference panel but not in the GWAS
were included; the minimum minor allele frequency was set to 0.01 and a max-
imum allowed distance of 250 k between LD blocks was used for variants to be
included in the same locus. For assigning variants to genes for gene-set enrichment
analyses, positional mapping was used with variants assigned to a gene if they were
within the gene start and end points (by setting the distance either side to 0 kb) and
only protein-coding genes were included in the mapping process. MAGMA gene-
set enrichment analysis, implemented in FUMA, adopts a competitive test of gene-
set enrichment using 10,894 gene sets obtained from MSigDB72. Tested gene sets
include BioCarta, REACTOME, KEGG and GO among others; a full list of gene
sets used by MSigDB can be found at http://software.broadinstitute.org/gsea/
msigdb/collections.jsp. Bonferroni correction for gene-set enrichment adjusted for
the number of gene sets tested and was applied to each phenotype separately.
Analysis of differentially expressed genes was based on data from GTEx v6 RNA-
seq data73. Enrichment analyses of the overlap with associations previously
reported through GWAS, using data from the GWAS Catalogue, was also imple-
mented through FUMA. Enrichment P-values for the proportion of overlapping
genes present was based on the NIH GWAS catalogue74.
Fine-mapping association signals. Fine-mapping analyses were performed using
FINEMAP v1.241 using the software’s shotgun stochastic search function and by
setting the maximum number of causal SNPs at each locus to 20. At each locus, we
included only those with P < 0.01 and within 500 Kb either side of the lead variant
to limit the number of SNPs in the analysis. We constructed the LD matrix by
calculating the Pearson correlation coefficient for all SNP–SNP pairs using SNP
dosages. Dosages were derived from the unrelated European subset of the full UK
Biobank imputed genotype probabilities (N= 379,769). We considered a SNP to be
causal if it’s log10 Bayes factor was >2, as recommended in the FINEMAP manual
(http://www.christianbenner.com/index_v1.2.html).
Alamut annotation and eQTL mapping. We performed variant annotation of our
fine-mapped loci using Alamut Batch v1.8 (Interactive Biosoftware, Rouen, France)
using all default options and genome assembly GRCh37. For each annotated
variant, we retained only the canonical (longest) transcript and reported the variant
location, coding effect and the predicted local splice site effect. To investigate
whether the fine-mapped SNPs were eQTLs, we searched for our SNPs in the
single-tissue cis-eQTL and multi-tissue eQTL datasets (v7), available at the GTEx
portal (https://www.gtexportal.org/home/datasets) for significant SNP-gene eQTL
associations. In the multi-tissue eQTL data, we reported a SNP as an eQTL for a
gene if the SNP-gene association was significant in the meta-analysis across all
tissues. Using the single-tissue cis-eQTL data, we performed a lookup of our fine-
mapped SNPs for significant SNP-gene associations in brain tissues only. For each
gene with a fine-mapped SNP significantly associated with expression levels, we
reported the tissue with the strongest evidence (lowest P-value) of association and
the correlation (r2) between the fine-mapped SNP and the tissue’s strongest eQTL
SNP.
Sensitivity analyses. To assess whether stratification was responsible for any of
the individual variant associations in a subset of the cohort, we performed multiple
sensitivity analyses in unrelated European subsets of the UK Biobank using
STATA. Relatedness was inferred using kinship coefficients provided by the UK
Biobank. The maximal set of unrelated individuals (<3rd degree) were put forward
for sensitivity analyses. The sensitivity analyses carried out were: (1) males only, (2)
females only (3) individuals younger than the median age (at start of the activity-
monitor wear period), (4) individuals older than the median age, (5) adjustment for
body mass index (BMI) (UK Biobank data field 21001), (6) adjusting for BMI and
lifestyle factors and (7) excluding individuals working shifts, taking medication for
sleep or psychiatric disorders, self-reporting a mental health or sleep disorder, or
diagnosed with depression, schizophrenia, bipolar disorder, anxiety disorders or
mood disorder in the HES data (see Supplementary Methods). Sensitivity analyses
were performed using fixed-effect models. Phenotypes were regressed against
dosage values of lead variants and the same covariates described for the main
BOLT-LMM GWAS. The first 5 within-European principal components were also
included as covariates to account for any subtle differences in ancestry. All
exclusions and adjustments were made using baseline records (taken at the
assessment centre).
Mendelian randomisation (MR). We performed two-sample MR, using the
inverse-variance weighted (IVW) approach75 as our main analysis method, and
MR-Egger75, weighted median estimation76 and penalised weighted median esti-
mation76 as sensitivity analyses in the event of unidentified pleiotropy of our
genetic instruments. Genetic variants that are robustly associated with the exposure
of interest may also influence the outcome through associations with other risk
factors for the outcome. This is known as “horizontal pleiotropy” and may bias MR
results. The assumptions of IVW are that there is either no horizontal pleiotropy
(under a fixed-effect model) or, if implemented under a random effects model due
to heterogeneity among the causal estimates, that (i) there is no correlation between
the strength of the association of the genetic instruments with the risk factor and
the magnitude of the pleiotropic effects, and (ii) the pleiotropic effects have an
average value of zero. Unbiased causal estimates can be obtained through MR-
Egger if just the first condition above holds by estimating and adjusting for non-
zero mean pleiotropy. If <50% of the weight in the analysis stems from variants
that are pleiotropic then a weighted median approach may be used as an alter-
native. Given the differences in assumptions, if the results from all methods are
broadly consistent, then our causal inference is strengthened.
In an effort to reduce the number of genetic instruments violating the above
assumptions, we used a newly described method77 to quantify, using a new iterative
weighting method, each instrument’s contribution to heterogeneity of the causal
IVW estimate. High heterogeneity in Cochran’s Q statistic, which should follow a
χ2n1 distribution for n instruments, indicates that either invalid (horizontally
pleiotropic) instruments have been included or that MR modelling assumptions
have been violated. We therefore excluded variants with an extreme Cochran’s Q
greater than the Bonferroni corrected threshold (QSNP>χ
2
10:05=n;1) prior to
performing MR analysis.
Ethics and consent. The UK Biobank was granted ethical approval by the North
West Multi-centre Research Ethics Committee (MREC) to collect and distribute
data and samples from the participants (http://www.ukbiobank.ac.uk/ethics/) and
covers the work in this study, which was performed under UK Biobank application
numbers 9072 and 16434. All participants included in these analyses gave informed
consent to participate. UK Biobank consent procedures are detailed at http://
biobank.ctsu.ox.ac.uk/crystal/field.cgi?id=200.
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Data availability
Summary statistics for the eight UK Biobank GWAS analyses can be found at http://
www.t2diabetesgenes.org/data/ and on the Sleep Disorder Knowledge Portal at http://
sleepdisordergenetics.org/informational/data/. The GGIR R script used to generate the
activity-monitor measures is provided in Supplementary Data 10 and isavailable with the
online version of this article.
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